South Korea · Delayed Price · Currency is KRW BioInfra Statistics
Total Valuation
BioInfra has a market cap or net worth of KRW 27.05 billion. The enterprise value is 26.82 billion.
| Market Cap | 27.05B |
| Enterprise Value | 26.82B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
BioInfra has 4.86 million shares outstanding.
| Current Share Class | 4.86M |
| Shares Outstanding | 4.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 51.53% |
| Owned by Institutions (%) | 0.57% |
| Float | 2.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.12 |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.33 |
| EV / Sales | 1.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.31 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.45.
| Current Ratio | 1.16 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.12 |
| Interest Coverage | -15.45 |
Financial Efficiency
Return on equity (ROE) is -15.76% and return on invested capital (ROIC) is -9.90%.
| Return on Equity (ROE) | -15.76% |
| Return on Assets (ROA) | -8.28% |
| Return on Invested Capital (ROIC) | -9.90% |
| Return on Capital Employed (ROCE) | -20.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.55 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.38B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.13% in the last 52 weeks. The beta is 0.83, so BioInfra's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -38.13% |
| 50-Day Moving Average | 5,784.60 |
| 200-Day Moving Average | 6,567.55 |
| Relative Strength Index (RSI) | 41.54 |
| Average Volume (20 Days) | 6,715 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioInfra had revenue of KRW 24.25 billion and -4.24 billion in losses. Loss per share was -871.09.
| Revenue | 24.25B |
| Gross Profit | 5.12B |
| Operating Income | -5.82B |
| Pretax Income | -6.61B |
| Net Income | -4.24B |
| EBITDA | -2.44B |
| EBIT | -5.82B |
| Loss Per Share | -871.09 |
Balance Sheet
The company has 10.92 billion in cash and 10.70 billion in debt, giving a net cash position of 224.75 million or 46.20 per share.
| Cash & Cash Equivalents | 10.92B |
| Total Debt | 10.70B |
| Net Cash | 224.75M |
| Net Cash Per Share | 46.20 |
| Equity (Book Value) | 23.88B |
| Book Value Per Share | 4,909.77 |
| Working Capital | 2.05B |
Cash Flow
In the last 12 months, operating cash flow was -3.57 billion and capital expenditures -1.48 billion, giving a free cash flow of -5.05 billion.
| Operating Cash Flow | -3.57B |
| Capital Expenditures | -1.48B |
| Free Cash Flow | -5.05B |
| FCF Per Share | -1,038.71 |
Margins
Gross margin is 21.12%, with operating and profit margins of -23.99% and -17.46%.
| Gross Margin | 21.12% |
| Operating Margin | -23.99% |
| Pretax Margin | -27.26% |
| Profit Margin | -17.46% |
| EBITDA Margin | -10.05% |
| EBIT Margin | -23.99% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 400.00, which amounts to a dividend yield of 7.27%.
| Dividend Per Share | 400.00 |
| Dividend Yield | 7.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 7.27% |
| Earnings Yield | -15.66% |
| FCF Yield | -18.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioInfra has an Altman Z-Score of 1.75 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.75 |
| Piotroski F-Score | 1 |